Nxstage Medical Earnings: Here’s Why Investors are Selling Shares Now
Nxstage Medical, Inc. (NASDAQ:NXTM) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 2.51%.
Nxstage Medical, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.06 in the quarter versus EPS of $-0.09 in the year-earlier quarter.
Revenue: Rose 10.93% to $65.46 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Nxstage Medical, Inc. reported adjusted EPS loss of $0.06 per share. By that measure, the company beat the mean analyst estimate of $-0.07. It beat the average revenue estimate of $64.67 million.
Quoting Management: “Our results reflect solid progress and early benefit from our strategic growth initiatives, including our new direct to patient marketing programs,” stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. “We believe our efforts to further penetrate both the US and international markets are on track to deliver 15 percent annual Home revenue growth in 2014 and beyond.”
Key Stats (on next page)…
Revenue increased 6.2% from $61.64 million in the previous quarter. EPS increased to $-0.06 in the quarter versus EPS of $-0.08 in the previous quarter.
Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a loss of $0.06 and has not changed. For the current year, the average estimate has moved down from a loss of $0.24 to a loss of $0.26 over the last ninety days.